2BBBullish & Bearish
PTC Therapeutics, Inc. (PTCT) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 61 out of 100.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
PTC Therapeutics, Inc.’s current 2BB score is 61 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 74 | High |
| Momentum | 69 | Improving |
| Financial strength | 37 | Weak |
| Quality | 100 | Very Strong |
| Risk | 42 | Moderate |
| CEO | Matthew B. Klein |
| Headquarters | Warren, New Jersey, United States |
| Founded | Jan 1, 1998 |
| Employees | 991 |
| 52-week range | $48.96 – $90.86 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-17 | — | 0.3987 | — | $325.99M |
| 2026-11-02 | — | 0.432 | — | $308.33M |
| 2026-07-30 | — | 0.3872 | — | $300.32M |
| 2026-05-07 | -0.03 | -0.4799 | $272.55M | $223.18M |